Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-22. (canceled)

23. (currently amended) A method of treating ~~wet age-related~~ macular degeneration, which comprises administering to a patient ~~in need thereof~~ having macular degeneration about ~~0.1 to about 2~~ 5 to about 50 mg per day of ~~4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione~~ 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione of the formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

24. (currently amended) The method of claim 23, wherein the compound is ~~4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione~~ 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione.

25. (previously presented) The method of claim 23, wherein the compound is a pharmaceutically acceptable salt.

26. (previously presented) The method of claim 23, wherein the compound is a pharmaceutically acceptable solvate.

27. (previously presented) The method of claim 23, wherein the compound is a pharmaceutically acceptable stereoisomer.

28. (previously presented) The method of claim 27, wherein the stereoisomer is an enantiomerically pure R isomer.

29. (previously presented) The method of claim 27, wherein the stereoisomer is an enantiomerically pure S isomer.

30. (previously presented) The method of claim 23, which further comprises administering a therapeutically effective amount of a second active agent.

31. (previously presented) The method of claim 30, wherein the second active agent is a steroid, a light sensitizer, an integrin, an antioxidant, an interferon, a xanthine derivative, a growth hormone, a neutrotrophic factor, a regulator of neovascularization, an anti-VEGF antibody, a prostaglandin, an antibiotic, a phytoestrogen, an anti-inflammatory compound or an antiangiogenesis compound.

32. (previously presented) The method of claim 30, wherein the second active agent is thalidomide, verteporfin, purlytin, an angiostatic steroid, rhuFab, interferon-2α or pentoxifylline, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

33. (previously presented) The method of claim 32, wherein the second active agent is thalidomide.

34. (previously presented) The method of claim 23, wherein the compound is administered before, during or after surgical intervention.

35. (previously presented) The method of claim 34, wherein the surgical intervention is light therapy, laser therapy, radiation therapy, retinal pigment epithelium transplantation, or foveal translocation.

36. (previously presented) The method of claim 23, wherein the compound is administered orally.

37. (previously presented) The method of claim 36, wherein the compound is administered in the form of a capsule or tablet.

38. canceled.

39. (currently amended) The method of claim ~~38~~ 23, wherein the compound is administered in an amount of from about ~~0.1 to about 1~~ 5 to about 25 mg per day.

40. (previously presented) The method of claim 23, wherein the compound is administered cyclically.

41. (new) The method of claim 23, wherein the compound is administered in the form of a capsule.

42. (new) The method of claim 41, wherein the compound is administered in the capsule of 5 mg, 10 mg, 15 mg or 25 mg.

43. (new) The method of claim 41 or 42, wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

44. (new) The method of claim 23, wherein the macular degeneration is wet macular degeneration, dry macular degeneration, age-related macular degeneration, age-related maculopathy, choroidal neovascularisation, retinal pigment epithelium detachment, atrophy of retinal pigment epithelium, Best's disease, vitelliform, Stargardt's disease, juvenile macular dystrophy, fundus flavimaculatus, Behr's disease, Sorsby's disease, Doyne's disease, honeycomb dystrophy, or macular damaging condition.